Immune Design Corp. (NASDAQ:IMDZ) was down 3.6% during trading on Friday . The company traded as low as $6.66 and last traded at $6.79, with a volume of 55,874 shares trading hands. The stock had previously closed at $7.04.

A number of equities research analysts have recently commented on IMDZ shares. Zacks Investment Research lowered shares of Immune Design Corp. from a “buy” rating to a “hold” rating in a research note on Friday, May 13th. Leerink Swann reissued a “buy” rating on shares of Immune Design Corp. in a research note on Thursday, May 12th. Wells Fargo & Co. reissued a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Jefferies Group reissued a “buy” rating and set a $20.00 target price on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Finally, Cowen and Company reissued a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $14.50.

The company’s market cap is $138.00 million. The stock has a 50-day moving average of $7.45 and a 200 day moving average of $10.75.

Immune Design Corp. (NASDAQ:IMDZ) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.03. On average, equities research analysts predict that Immune Design Corp. will post ($2.70) EPS for the current year.

A hedge fund recently raised its stake in Immune Design Corp. stock. RS Investment Management Co. LLC raised its stake in Immune Design Corp. (NASDAQ:IMDZ) by 12.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,108,576 shares of the company’s stock after buying an additional 122,910 shares during the period. RS Investment Management Co. LLC owned 5.50% of Immune Design Corp. worth $22,260,000 at the end of the most recent reporting period.

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.